|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||189.55 - 191.58|
|52-week range||139.07 - 201.20|
|PE ratio (TTM)||33.13|
|Earnings date||29 Jan 2018 - 2 Feb 2018|
|Forward dividend & yield||0.60 (0.31%)|
|1y target est||219.07|
IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.
Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.
On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.
The Waltham, Massachusetts-based company said it had profit of $1.34 per share. Earnings, adjusted for one-time gains and costs, came to $2.31 per share. The results topped Wall Street expectations. The ...
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.
The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.
Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.
NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.
The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.
The gloomy eco-political scenario in the United States and Europe points toward the fact that emerging geographies are playing a crucial role in the growth of the MedTech space globally.
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.
The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.
Morgan Stanley equity strategists picked nine stocks they say could be movers in the early weeks of earnings season.